يعرض 1 - 6 نتائج من 6 نتيجة بحث عن '"авибактам"', وقت الاستعلام: 0.34s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المساهمون: Исследование проводилось при поддержке независимого медицинского гранта компании «Пфайзер»

    المصدر: PULMONOLOGIYA; Том 32, № 5 (2022); 737-744 ; Пульмонология; Том 32, № 5 (2022); 737-744 ; 2541-9617 ; 0869-0189

    وصف الملف: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/3662/3447; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/3662/1323; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/3662/1324; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/3662/1325; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/3662/1326; Adeboyeku D., Jones A.L., Hodson M.E. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J. Cyst. Fibros. 2011; 10 (1): 25–30. DOI:10.1016/j.jcf.2010.09.003.; Mandell L.A., Wunderink R.G., Anzueto A. et al. Infectious diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44 Suppl. 2 (Suppl. 2): S27–S72. DOI:10.1086/511159.; Кондратьева Е.И., Амелина Е.Л., Чернуха М.Ю. и др. Обзор клинических рекомендаций «Кистозный фиброз (муковисцидоз)» (2020). Пульмонология. 2021; 31 (2): 135–147. DOI:10.18093/0869-0189-2021-31-2-135-146.; Чеботарь И.В., Бочарова Ю.А., Маянский Н.А. Механизмы резистентности Pseudomonas aeruginosa к антибиотикам и их регуляция. Клиническая микробиология и антимикробная химиотерапия. 2017; 19 (4): 308–319. Доступно на: https://cmac-journal.ru/publication/2017/4/cmac-2017-t19-n4-p308/cmac-2017-t19-n4-p308.pdf; Atkin S.D., Abid S., Foster M. et al. Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. Infect. Drug Resist. 2018; 11: 1499–1510. DOI:10.2147/IDR.S173804.; Papp-Wallace K.M., Becka S.A., Zeiser E.T. et al. Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect. Dis. 2017; 3 (7): 502–511. DOI:10.1021/acsinfecdis.7b00020.; Стецюк О.У., Андреева И.В., Лекманов А.У., Хайкина Е.В. Цефтазидим-авибактам в педиатрии — «портрет» пациента: кому и когда? Клиническая микробиология и антимикробная химиотерапия. 2021; 23 (2): 173–183. DOI:10.36488/cmac.2021.2.173-183.; Spoletini G., Etherington C., Shaw N. et al. Use of ceftazidime/ avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series. J. Antimicrob. Chemother. 2019; 74 (5): 1425–1429. DOI:10.1093/jac/dky558.; Soriano A., Carmeli Y., Omrani A.S. et al. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect. Dis. Ther. 2021; 10 (4): 1989–2034. DOI:10.1007/s40121-021-00507-6.; Sader H.S., Duncan L.R., Doyle T.B., Castanheira M. Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. JAC Antimicrob. Resist. 2021; 3 (3): dlab126. DOI:10.1093/jacamr/dlab126.; Okoliegbe I.N., Hijazi K., Cooper K. et al. Trends of antimicrobial resistance and combination susceptibility testing of multidrug-resistant pseudomonas aeruginosa isolates from cystic fibrosis patients: a 10-year update. Antimicrob. Agents Chemother. 2021; 65 (6): e02483- 20. DOI:10.1128/AAC.02483-20.; Lasko M.J., Huse H.K., Nicolau D.P., Kuti J.L. Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis. Ann. Clin. Microbiol. Antimicrob. 2021; 20 (1): 9. DOI:10.1186/s12941-021-00415-0.; Ekkelenkamp M.B., Cantón R., Díez-Aguilar M. et al. Susceptibility of Pseudomonas aeruginosa recovered from cystic fibrosis patients to Murepavadin and 13 comparator antibiotics. Antimicrob Agents Chemother. 2020; 64 (2): e01541-19. DOI:10.1128/AAC.01541-19.; Cantón-Bulnes M.L., Hurtado Martínez Á., López-Cerero L. et al. A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy. Transpl. Infect. Dis. 2019; 21 (2): e13034. DOI:10.1111/tid.13034.; Los-Arcos I., Len O., Martín-Gómez M.T. et al. Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam. Infection. 2019; 47 (2): 289–292. DOI:10.1007/s15010-018-1261-y.; Tamma P.D., Fan Y., Bergman Y. et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam. Antimicrob. Agents Chemother. 2018; 62 (4): e02213- 17. DOI:10.1128/AAC.02213-17.; https://journal.pulmonology.ru/pulm/article/view/3662

  3. 3
    Academic Journal

    المصدر: Siberian journal of oncology; Том 20, № 4 (2021); 160-165 ; Сибирский онкологический журнал; Том 20, № 4 (2021); 160-165 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-4

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/1879/896; Robinson R., Marconi L., MacPepple E., Hakenberg O.W., Watkin N., Yuan Y., Lam T., MacLennan S., Adewuyi T.E., Coscione A., Minhas S.S., Compérat E.M., Necchi A. Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. Eur Urol. 2018 Jul; 74(1): 76–83. doi:10.1016/j.eururo.2018.04.003.; Backes D.M., Kurman R.J., Pimenta J.M., Smith J.S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009 May; 20(4): 449–57. doi:10.1007/s10552-008-9276-9.; Chaux A., Netto G.J., Rodríguez I.M., Barreto J.E., Oertell J., Ocampos S., Boggino H., Codas R., Xavier Bosch F., de Sanjose S., Muñoz N., Hildesheim A., Cubilla A.L. Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol. 2013 Aug; 31(4): 861–7. doi:10.1007/s00345-011-0802-0.; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 г. (заболеваемость и смертность). М., 2016. 208 c.; d'Ancona C.A., de Lucena R.G., Querne F.A., Martins M.H., Denardi F., Netto N.R.Jr. Long-term followup of penile carcinoma treated with penectomy and bilateral modified inguinal lymphadenectomy. J Urol. 2004 Aug; 172(2): 498–501; discussion 501. doi:10.1097/01.ju.0000132239.28989.e1.; Ornellas A.A., Seixas A.L., Marota A., Wisnescky A., Campos F., de Moraes J.R. Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol. 1994 May; 151(5): 1244–9. doi:10.1016/s0022-5347(17)35222-9.; Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol. 1993 Nov; 72(5 Pt 2): 817–9. doi:10.1111/j.1464-410x.1993.tb16273.x.; Solsona E., Algaba F., Horenblas S., Pizzocaro G., Windahl T.; European Association of Urology. EAU Guidelines on Penile Cancer. Eur Urol. 2004 Jul; 46(1): 1–8. doi:10.1016/j.eururo.2004.03.007.; Stancik I., Holtl W. Penile cancer: A review of the recent literature. Curr Opin Urol. 2003; 13(6): 467–72.; The European Association of Urology (EAU). Guidelines Methodology. 2008; р. 58–69.; Григорьевская З.В., Петухова И.Н., Дьякова С.А., Дмитриева Н.В. Эпидемиология внутрибольничных инфекций в онкологическом стационаре, вызванных высокорезистентными (XDR) штаммами А. baumannii. Сибирский онкологический журнал. 2016; 15(3): 62–66. doi:10.21294/1814-4861-2016-15-3-62-66.; Григорьевская З.В., Петухова И.Н., Багирова Н.С., Шильникова И.И., Терещенко И.В., Григорьевский Е.Д., Дмитриева Н.В. Нозокомиальные инфекции у онкологических больных: проблема нарастающей резистентности грамотрицательных микроорганизмов. Сибирский онкологический журнал. 2017; 16(1): 91–97. doi:10.21294/1814-4861-2017-16-1-91-97.; Григорьевская З.В. Актуальность проблемы госпитальных инфекций в онкологической клинике. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2013; 24(3–4): 46–49.; https://www.siboncoj.ru/jour/article/view/1879

  4. 4
    Academic Journal

    المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 8, № 2 (2021); 61-72 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 8, № 2 (2021); 61-72 ; 2413-5496 ; 2311-1267

    وصف الملف: application/pdf

    Relation: https://journal.nodgo.org/jour/article/view/721/660; Скоробогатова Е.В., Балашов Д.Н., Трахтман П.Е., Масчан А.А., Румянцев А.Г., Киргизов К.И. Итоги двадцатилетнего опыта трансплантации гемопоэтических стволовых клеток у детей. Педиатрия. Журнал им. ГН. Сперанского 2011;90(4):12-6.; Афанасьев Б.В., Зубаровская Л.С., Моисеев И.С. Аллогенная трансплантация гемопоэтических стволовых клеток у детей: настоящее, проблемы и перспективы. Российский журнал детской гематологии и онкологии 2015;2(2):28-42. doi:10.17650/2311-1267-2015-2-228-42.; Multani A., Allard L.S., Wangjam T., Sica R.A., Epstein D.J., Rezvani A.R., Ho D.Y. Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study. Blood Adv 2019;3(22):3602-12. doi:10.1182/bloodadvances.2019000634.; Ge J., Yang T., Zhang L., Zhang X., Zhu X., Tang B., Wan X., Tong J., Song K., Yao W., Sun G., Sun Z., Liu H. The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study. BMC Infect Dis 2018;18(1):654. doi:10.1186/s12879-018-3575-x.; Mikulska M., Del Bono V., Bruzzi P., Raiola A. M., Gualandi F., Van Lint M.T., Bacigalupo A., Viscoli C. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection 2012;40(3):271-8. doi:10.1007/s15010-011-0229-y.; Wang L., Wang Y., Fan X., Tang W., Hu J. Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Single Center Retrospective Cohort Study. Medicine (Baltimore) 2015;94(45):e1931. doi:10.1097/MD.0000000000001931.; Riccardi N., Rotulo G.A., Castagnola E. Definition of Opportunistic Infections in Immunocompromised Children on the Basis of Etiologies and Clinical Features: A Summary for Practical Purposes. Curr Pediatr Rev 2019;15(4):197-206. doi:10.2174/1573396315666190617151745.; Heinz W.J., Buchheidt D., Christopeit M., von Lilienfeld-Toal M., Cornely O.A., Einsele H., Karthaus M., Link H., Mahlberg R., Neumann S., Ostermann H., Penack O., Ruhnke M., Sandherr M., Schiel X., Vehreschild J.J., Weissinger F., Maschmeyer G. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2017;96(11):1775-92. doi:10.1007/s00277-017-3098-3.; Mikulska M., Viscoli C., Orasch C., Livermore D.M., Averbuch D., Cordonnier C., Akova M.; Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014;68(4):321-31. doi:10.1016/j.jinf.2013.12.006.; Girmenia C., Bertaina A., Piciocchi A., Perruccio K., Algarotti A., Busca A., Cattaneo C., Raiola A.M., Guidi S., Iori A.P., Candoni A., Irrera G., Milone G., Marcacci G., Scime R., Musso M., Cudillo L., Sica S., Castagna L., Corradini P., Marchesi F., Pastore D., Alessandrino E.P., Annaloro C., Ciceri F., Santarone S., Nassi L., Farina C., Viscoli C., Rossolini G.M., Bonifazi F., Rambaldi A.; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis 2017;65(11):1884-96. doi:10.1093/cid/cix690.; Martm-Pena A., Aguilar-Guisado M., Espigado I., Parody R., Miguel Cisneros J. Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clin Transplant 2011;25(3):468-74. doi:10.1111/j.1399-0012.2010.01286.x.; Gomez S., Fynn A.B., Fernanda S., Cecilia V., Sung L. Early bacterial and fungal infection in children receiving allogeneic stem cell transplantation for acute lymphoblastic leukemia in Argentina. Pediatr Transplant 2018;22(1). doi:10.1111/petr.13070.; Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., Raad I.I., Rolston K.V., Young J.A., Wingard J.R.; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52(4):e56-93. doi:10.1093/cid/cir073.; Averbuch D., Tridello G., Hoek J., Mikulska M., Akan H., Yanez San Segundo L., Pabst T., Oz^elik T., Klyasova G., Donnini I., Wu D., Gulbas Z., Zuckerman T., Botelho de Sousa A., Beguin Y., Xhaard A., Bachy E., Ljungman P., de la Camara R., Rascon J., Ruiz Camps I., Vitek A., Patriarca F., Cudillo L., Vrhovac R., Shaw P.J., Wolfs T., O'Brien T., Avni B., Silling G., Al Sabty F., Graphakos S., Sankelo M., Sengeloev H., Pillai S., Matthes S., Melanthiou F., Iacobelli S., Styczynski J., Engelhard D., Cesaro S. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis 2017;65(11):1819-28. doi:10.1093/cid/cix646.; Forcina A., Baldan R., Marasco V., Cichero P., Bondanza A., Noviello M., Piemontese S., Soliman C., Greco R., Lorentino F., Giglio F., Messina C., Carrabba M., Bernardi M., Peccatori J., Moro M., Biancardi A., Nizzero P., Scarpellini P., Cirillo D.M., Mancini N., Corti C., Clementi M., Ciceri F. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplant 2017;52(1):114-9. doi:10.1038/bmt.2016.234.; Sadowska-Klasa A., Piekarska A., Prejzner W., Bieniaszewska M., Hellmann A. Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation. Ann Hematol 2018;97(3):509-17. doi:10.1007/s00277-017-3205-5.; Scheich S., Lindner S., Koenig R., Reinheimer C., Wichelhaus T.A., Hogardt M., Besier S., Kempf V.A.J., Kessel J., Martin H., Wilke A.C., Serve H., Bug G., Steffen B. Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Cancer 2018;124(2):286-96. doi:10.1002/cncr.31045.; Forcina A., Lorentino F., Marasco V., Oltolini C., Marcatti M., Greco R., Lupo-Stanghellini M.T., Carrabba M., Bernardi M., Peccatori J., Corti C., Ciceri F. Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2018;24(7):1476-82. doi:10.1016/j.bbmt.2018.02.021.; Averbuch D., Cordonnier C., Livermore D.M., Mikulska M., Orasch C., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O., Engelhard D., Akova M.; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multiresistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 2013;98(12):1836-47. doi:10.3324/haematol.2013.091330.; Mazuski J.E., Gasink L.B., Armstrong J., Broadhurst H., Stone G.G., Rank D., Llorens L., Newell P., Pachl J. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis 2016;62(11):1380-9. doi:10.1093/cid/ciw133.; Козлов Р.С., Стецюк О.У., Андреева И.В. Цефтазидим-авибактам: новые «правила игры» против полирезистентных грамотрицательных бактерий. Клиническая микробиология и антимикробная химиотерапия 2018;20(1):24-34. doi:10.36488/cmac.2018.1.24-34.; Caston J.J., Lacort-Peralta I., Martm-Davila P., Loeches B., Tabares S., Temkin L., Torre-Cisneros J., Pano-Pardo J.R. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis 2017;59:118-23. doi:10.1016/j.ijid.2017.03.021.; Shaw E., Rombauts A., Tubau F., Padulles A., Camara J., Lozano T., Cobo-Sacristan S., Sabe N., Grau I., Rigo-Bonnin R., Dominguez M.A., Carratala J. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2018;73(4):1104-6. doi:10.1093/jac/dkx496.; Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.D., Coopersmith C.M., Hotchkiss R.S., Levy M.M., Marshall J.C., Martin G.S., Opal S.M., Rubenfeld G.D., van der Poll T., Vincent J.L., Angus D.C. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315(8):801-10. doi:10.1001/jama.2016.0287.; Satlin M.J., Cohen N., Ma K.C., Gedrimaite Z., Soave R., Askin G., Chen L., Kreiswirth B.N., Walsh T.J., Seo S.K. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect 2016;73(4):336-45. doi:10.1016/j.jinf.2016.07.002.; Mokart D., Slehofer G., Lambert J., Sannini A., Chow-Chine L., Brun J.P., Berger P., Duran S., Faucher M., Blache J.L., Saillard C., Vey N., Leone M. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med 2014;40(1):41-9. doi:10.1007/s00134-013-3148-9.; Orasch C., Averbuch D., Mikulska M., Cordonnier C., Livermore D.M., Gyssens I.C., Klyasova G., Engelhard D., Kern W., Viscoli C., Akova M., Marchetti O.; 4th European Conference on Infections in Leukemia (ECIL-4); joint venture of Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (IDWP-EBMT); Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (IDG-EORTC); International Immunocompromised Host Society (ICHS); European Leukemia Net (ELN) and European Study Group on Infections in Immunocompromised Hosts of the European Society for Clinical Microbiology and Infectious Diseases (ESGICH-ESCMID). Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clin Microbiol Infect 2015;21(3):e25-7. doi:10.1016/j.cmi.2014.10.014.; D'Amico F., Soverini M., Zama D., Consolandi C., Severgnini M., Prete A., Pession A., Barone M., Turroni S., Biagi E., Brigidi P., Masetti R., Rampelli S., Candela M. Gut resistome plasticity in pediatric patients undergoing hematopoietic stem cell transplantation. Sci Rep 2019;9(1):5649. doi:10.1038/s41598-019-42222-w.; Karaiskos I., Giamarellou H. Multidrug-resistant and extensively drugresistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014;15(10):1351-70. doi:10.1517/14656566.2014.914172.; Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O., Engelhard D., Akova M.; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013;98(12):1826-35. doi:10.3324/haematol.2013.091025. Erratum in: Haematologica 2014;99(2):400. PMID: 24323983.; https://journal.nodgo.org/jour/article/view/721

  5. 5
    Academic Journal
  6. 6